387 related articles for article (PubMed ID: 15143368)
41. Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies.
Karapanagiotou EM; Pelekanou E; Charpidou A; Tsaganos T; Anagnostou V; Plachouras D; Giamarellos-Bourboulis EJ; Syrigos KN
Anticancer Res; 2008; 28(2B):1411-5. PubMed ID: 18505088
[TBL] [Abstract][Full Text] [Related]
42. Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer patients.
Kaya A; Gülbay BE; Gürkan OU; Celik G; Savaş H; Savaş I
Tuberk Toraks; 2003; 51(4):380-4. PubMed ID: 15143385
[TBL] [Abstract][Full Text] [Related]
43. Complement as a predictor of further miscarriage in couples with recurrent miscarriages.
Sugiura-Ogasawara M; Nozawa K; Nakanishi T; Hattori Y; Ozaki Y
Hum Reprod; 2006 Oct; 21(10):2711-4. PubMed ID: 16790609
[TBL] [Abstract][Full Text] [Related]
44. Serum concentrations of immunoglobulins and complement components in patients with recurrence after resection of gastric carcinoma.
Janssen CW; Tønder O; Matre R
Cancer Detect Prev; 1987; 10(3-4):303-9. PubMed ID: 3568028
[TBL] [Abstract][Full Text] [Related]
45. Prognostic significance of preoperative serum carcinoembryonic antigen level in lung adenocarcinoma but not squamous cell carcinoma.
Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T
Ann Thorac Cardiovasc Surg; 2004 Apr; 10(2):76-80. PubMed ID: 15209547
[TBL] [Abstract][Full Text] [Related]
46. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
47. [Serum immunoglobulins and various components of complement in patients with insulin-dependent diabetes mellitus].
Pietruska Z; Kinalska I; Jabłońska E; Czaczkowska T
Przegl Lek; 1989; 46(3):338-41. PubMed ID: 2772239
[TBL] [Abstract][Full Text] [Related]
48. CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients.
Muley T; Dienemann H; Ebert W
Anticancer Res; 2004; 24(3b):1953-6. PubMed ID: 15274383
[TBL] [Abstract][Full Text] [Related]
49. Serum immunoglobin and complement levels in Ghanaian sickle cell patients in the steady asymptomatic state.
Akanmori BD; Adjei AA; Nyarko AK; Ankra-Badu G; Gyan B; Yamamoto S
East Afr Med J; 1991 May; 68(5):378-82. PubMed ID: 1935733
[TBL] [Abstract][Full Text] [Related]
50. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
51. A multiparametric serum kallikrein panel for diagnosis of non-small cell lung carcinoma.
Planque C; Li L; Zheng Y; Soosaipillai A; Reckamp K; Chia D; Diamandis EP; Goodglick L
Clin Cancer Res; 2008 Mar; 14(5):1355-62. PubMed ID: 18316555
[TBL] [Abstract][Full Text] [Related]
52. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies.
Petridou ET; Mitsiades N; Gialamas S; Angelopoulos M; Skalkidou A; Dessypris N; Hsi A; Lazaris N; Polyzos A; Syrigos C; Brennan AM; Tseleni-Balafouta S; Mantzoros CS
Oncology; 2007; 73(3-4):261-9. PubMed ID: 18424891
[TBL] [Abstract][Full Text] [Related]
53. High serum concentrations of Sialyl Lewisx predict multilevel N2 disease in non-small-cell lung cancer.
Mizuguchi S; Inoue K; Iwata T; Nishida T; Izumi N; Tsukioka T; Nishiyama N; Uenishi T; Suehiro S
Ann Surg Oncol; 2006 Jul; 13(7):1010-8. PubMed ID: 16788764
[TBL] [Abstract][Full Text] [Related]
54. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
55. [Components of complement in patients with immediate hypersensitivity].
Anania A; Massobrio AM; Cascio B; Bosso E; Cascio G
Minerva Med; 1998 Mar; 89(3):77-81. PubMed ID: 9575333
[TBL] [Abstract][Full Text] [Related]
56. The prognostic value of preoperative serum immunoglobulin and complement component concentrations in patients with gastric carcinoma.
Janssen CW; Tønder O; Matre R
Acta Chir Scand; 1985; 151(1):57-61. PubMed ID: 3984657
[TBL] [Abstract][Full Text] [Related]
57. Elevated serum beta-defensins concentrations in patients with lung cancer.
Arimura Y; Ashitani J; Yanagi S; Tokojima M; Abe K; Mukae H; Nakazato M
Anticancer Res; 2004; 24(6):4051-7. PubMed ID: 15736451
[TBL] [Abstract][Full Text] [Related]
58. Increases in immunoglobulin and complement in patients with esophageal or gastric cancer.
Saito T; Kuwahara A; Kinoshita T; Shigemitsu Y; Shimoda K; Miyahara M; Kobayashi M
Surg Today; 1992; 22(6):537-42. PubMed ID: 1472794
[TBL] [Abstract][Full Text] [Related]
59. Immunological evaluation of renal transplant patients: changes in levels of beta-2-microglobulin, immunoglobulins and complement components during graft rejection.
Barnes RM; Hart CA; Alexander LC; Steen S
J Clin Lab Immunol; 1983 Sep; 12(1):17-22. PubMed ID: 6355478
[TBL] [Abstract][Full Text] [Related]
60. Clinicopathologic study of resected, peripheral, small-sized, non-small cell lung cancer tumors of 2 cm or less in diameter: pleural invasion and increase of serum carcinoembryonic antigen level as predictors of nodal involvement.
Inoue M; Minami M; Shiono H; Sawabata N; Ideguchi K; Okumura M
J Thorac Cardiovasc Surg; 2006 May; 131(5):988-93. PubMed ID: 16678580
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
